Healthcare Dec 16, 2020 02:27 PM (GMT+8) · EqualOcean
Recently, xuanming announced the completion of a 100 million round of financing. This round of financing is led by Huagai capital and juming venture capital. The old shareholder Tongchuang Weiye continues to invest, Zhongguancun Qihang capital and fangfu capital follow. It is reported that the funds raised will be mainly used for the construction of Suzhou GMP plant of xuanming cells and the market expansion of one-stop cdmo service project of genetic drugs, so as to continuously promote the development and innovation of new carrier technologies and processes, improve the production capacity of GMP grade plasmids, lentivirus, AAV, adenovirus and other products, and accelerate the process of new drug development and listing of domestic and international gene therapy enterprises. Xuanming cell is mainly engaged in the development and application of gene and cell therapy technology, and provides the whole process service from research and development to clinical application of gene therapy drugs. At present, in Jinan pharmaceutical Valley Industrial Park, xuanming cell has a GMP plant with a construction area of 2500 square meters in the first phase, with 10 production lines, including plasmid production line, virus production line and cell preparation production line.

This text is a result of machine translation.